Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy

Purpose. To show the long-term results of intravitreal ranibizumab combined with photodynamic therapy (PDT) for the treatment of polypoidal choroidal vasculopathy (PCV).Methods. We analyzed the progress of two patients for 36 and 58 months, respectively. We only used PDT for the treatment in the area of the active PCV or “hot spot” evident on the indocyanine green angiography (ICGA). The spot size was chosen so as to cover only the active neovascular lesion. We combined intravitreal ranibizumab with PDT when PCV remained active without visible polyps in ICGA or without a response to PDT.Conclusion. Administration, as required, of verteporfin photodynamic therapy combined with intravitreal ranibizumab is an effective treatment for symptomatic polypoidal choroidal vasculopathy. These data need to be confirmed in large, prospective, and controlled clinical trials which are randomized and carried out over a long period.

Download Full-text

Long-term results of photodynamic therapy or ranibizumab for polypoidal choroidal vasculopathy in LAPTOP study

British Journal of Ophthalmology ◽

10.1136/bjophthalmol-2018-312419 ◽

2018 ◽

Vol 103 (6) ◽

pp. 844-848 ◽

Cited By ~ 10

Author(s):

Noriko Miyamoto ◽

Michiko Mandai ◽

Akio Oishi ◽

Shunichiro Nakai ◽

Shigeru Honda ◽

...

Keyword(s):

Photodynamic Therapy ◽

Polypoidal Choroidal Vasculopathy ◽

Long Term Results ◽

Intravitreal Ranibizumab ◽

Macular Atrophy ◽

Long Term Effect ◽

First Choice ◽

Choroidal Vasculopathy

Background/aimWe previously reported that ranibizumab performed better on visual prognosis than photodynamic therapy (PDT) in a Ranibizumab (Lucentis) And Photodynamic Therapy On Polypoidal choroidal vasculopathy (LAPTOP) study. To determine if the first-choice treatment, either PDT or intravitreal ranibizumab, has a long-term effect in patients with polypoidal choroidal vasculopathy (PCV).MethodsWe reviewed medical records of patientsrandomised to either PDT (29 eyes) or ranibizumab (27 eyes) from July 2009 to June 2011 in LAPTOP study. Retreatment or switching to other treatments were at the investigator’s discretion after release from the 2-year LAPTOP study up to 5years. We evaluated visual acuity (VA), continuity of initial treatment, percentage of dry macula achievement and macular atrophy at 5 years.ResultsThe logarithm of minimal angle of resolution VA was 0.56 in the PDT and 0.44 in the ranibizumab groups at baseline (p=0.101) and was 0.55 and 0.28 at 5years, respectively (p<0.05). More than 70% of the patients converted to aflibercept in following years. Achievement percentages of dry macula were 74% (PDT) and 63% (ranibizumab) at 5years, and macular atrophy was detected in 78% (PDT) and 60% (ranibizumab) with a mean area of 7.7 and 3.5 mm2, respectively (p=0.155).ConclusionsThe better VA in the initial ranibizumab group compared with the PDT group at 2 years was retained at the 5-year follow-up.

Download Full-text

Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen

BMC Ophthalmology ◽

10.1186/s12886-018-0801-7 ◽

2018 ◽

Vol 18 (1) ◽

Cited By ~ 1

Author(s):

Kunbei Lai ◽

Ying Li ◽

Lijun Zhou ◽

Xiaojin Zhong ◽

Chuangxin Huang ◽

...

Keyword(s):

Photodynamic Therapy ◽

Polypoidal Choroidal Vasculopathy ◽

Intravitreal Ranibizumab ◽

Choroidal Vasculopathy

Download Full-text

Visual Parameters and Retinal Morphology for Polypoidal Choroidal Vasculopathy Pre- and Post-Intravitreal Ranibizumab with or without Photodynamic Therapy: A Short-Term Prospective Study

International Journal of Environmental Research and Public Health ◽

10.3390/ijerph18052581 ◽

2021 ◽

Vol 18 (5) ◽

pp. 2581

Author(s):

Rituparna Ghoshal ◽

Sharanjeet Sharanjeet-Kaur ◽

Norliza Mohamad Fadzil ◽

Somnath Ghosh ◽

Nor Fariza Ngah ◽

...

Keyword(s):

Photodynamic Therapy ◽

Prospective Study ◽

Polypoidal Choroidal Vasculopathy ◽

Reading Speed ◽

Pigment Epithelium ◽

Post Treatment ◽

Base Line ◽

Intravitreal Ranibizumab ◽

Pre Treatment ◽

Choroidal Vasculopathy

The objective of this study was to compare visual parameters and retinal layers’ morphology pre-treatment (baseline) and 6 months post-treatment in polypoidal choroidal vasculopathy (PCV) eyes. A single centre, longitudinal, prospective study was conducted at a public tertiary hospital of Malaysia. Visual parameters including distance and near visual acuity (DVA and NVA), contrast sensitivity (CS), reading speed (RS), and different qualitative and quantitative optical coherence tomography (OCT) parameters were evaluated pre- and 6 months post-treatment. Thirty-three naïve PCV eyes of 32 patients (mean age of 67.62 years) were evaluated pre- and post-treatment of intravitreal ranibizumab with and without photodynamic therapy. After treatment, sub retinal fluid decreased from 27 eyes (84.35%) at baseline to 7 eyes (21.88%) at 6 months while pigment epithelium detachment decreased from 32 eyes (100%) at base line to 15 eyes (46.87%) at 6 months. Mean pre-treatment quantitative morphological OCT retinal parameters including thickness and volume of central sub field, center thickness, center minimum, and maximum thickness reduced significantly. Similarly, all visual parameters including DVA, NVA, CS, and RS showed statistically significant improvement. While 89% of the eyes showed improvement in CS, 78%, 71%, and 65% of the eyes showed improvement in NVA, RS, and DVA, respectively. Thus, CS was the most treatment responsive visual parameter.

Download Full-text

Evaluation of long-term outcome and prognostic factors of feline squamous cell carcinomas treated with photodynamic therapy using liposomal phosphorylated meta-tetra(hydroxylphenyl)chlorine

Journal of Feline Medicine and Surgery ◽

10.1177/1098612x17752196 ◽

2018 ◽

Vol 20 (12) ◽

pp. 1100-1104 ◽

Cited By ~ 2

Author(s):

Irene Flickinger ◽

Eva Gasymova ◽

Simona Dietiker-Moretti ◽

Alexander Tichy ◽

Carla Rohrer Bley

Keyword(s):

Photodynamic Therapy ◽

Prognostic Factors ◽

Squamous Cell ◽

Tumour Response ◽

Dose Intensity ◽

Treatment Intensity ◽

Term Outcome ◽

Long Term Outcome ◽

Tumour Control

Objectives The aim of this study was to evaluate the efficacy, long-term outcome and prognostic factors of feline squamous cell carcinoma (SCC) treated with photodynamic therapy (PDT). Methods Cats with histologically verified SCC of the head and neck received an intravenous injection of liposomal phosphorylated meta-tetra(hydroxylphenyl)chlorine (mTHPC) and 4 h later 652 nm light was delivered by a diode laser. One group received ⩽10 J/cm2, the other 20 J/cm2. Tumour response and duration were analysed with stage, tumour diameter, location and treatment intensity as prognostic factors. Results In total, 63 lesions in 38 cats underwent treatment with ⩽10 J/cm2 (n = 22) and 20 J/cm2 (n = 41). Overall response rate was 84% (complete remission 61%, partial remission 22%) with a mean progression-free interval of 35 months (median not reached) and a median overall survival time of 40 months (95% confidence interval 33–47). With regard to tumour stage, invasiveness yielded a highly significant worse outcome ( P <0.017). All patients with invasive tumours showed progression at less than 6 months. Larger lesions were associated with inferior control and treatment intensity, and tumour location did not influence response and duration. Conclusions and relevance PDT using a systemic photosensitiser leads to excellent long-term tumour control in the majority of cats. However, invasive and large tumours had a clearly inferior outcome, even if treated with the higher-dose intensity. This suggests that advanced lesions are not indications for PDT.

Download Full-text